Patent application number | Description | Published |
20080261234 | Peptides and their use in assays for cardiovascular disease - A peptide having affinity for oxidised low density lipoprotein, in cyclised or multimeric form is useful in an enzyme immunosolvent assay, to detect oxLDL which is a marker of coronary heart disease. | 10-23-2008 |
20080280363 | Pseudotyped Baculovirus and its Use - A viral G protein-pseudotyped baculovirus, in which the G protein is truncated and comprises the ectodomain, transmembrane domain and cytoplasmic tail domain. Such a baculovirus can be used for transduction of cells and for gene therapy. | 11-13-2008 |
20080280783 | Baculovirus-Based Gene Libraries - A nucleotide molecule comprising a selectable gene flanked by anL1 and anL2 attachment sites of a bacteriophage and additionally comprising an origin of replication. This can be used to create a baculovirus-based gene library. | 11-13-2008 |
20080305999 | Therapeutic use of growth factor, and delivery device, especially for the treatment of intimal hyperplasia - Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered. | 12-11-2008 |
20090011509 | INTEGRASE FUSION PROTEINS AND THEIR USE WITH INTEGRATING GENE THERAPY - In a method of targeting intergration of a transgene comprising retrovirus-like DNA into a eukaryotic genome, the genome is cleared by an endonuclease and the transgene is introduced at the site of cleavage, wherein the endonuclease is specific to a site in an abundant rDNA locus and is fused to an integrase that mediates the introduction of the transgene. The fusion protein may be new. | 01-08-2009 |
20090011984 | Biotin-binding receptor molecules - The subject invention pertains to a transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity, and methods of use. The protein can be expressed in a cell, thereby targeting a biotinylated drug. | 01-08-2009 |
20090047733 | Avidin-Pseudotyped Viral Vectors and Their Use - The present invention pertains to an avidin-pseudotyped virus, and especially baculovirus, useful for delivery of foreign genes etc. The present invention also pertains to vectors comprising respective cassettes for pseudotyping, mammalian gene expression and insect gene expression in baculovirus. | 02-19-2009 |
20090176660 | Engineered Baculoviruses and Their Use - Baculovirus is engineered so that the capsid displays one or more heterologous peptides or protein. Such baculovirus can be used to deliver therapeutics, and in functional genomics. | 07-09-2009 |
20100003746 | Production of Lentiviral Vectors - The present invention is a method of generating a lentivirus vector, comprising cloning each of a leotivimus transfer construct, gag, pol, an envelope protein and rev respectively into the same or different baculoviruses, and transducing a producer cell with the or each baculovirus. | 01-07-2010 |
20100221791 | Method for Incorporating Proteins Into Lentivirus Vectors - The present invention is a method for incorporating an integrase-fusion protein into a third-generation lentivirus vector, comprising: (i) transfecting a vector packaging plasmid into a producer cell, wherein the vector packaging plasmid contains a lentivirus transfer construct and a gene encoding the integrase-fusion protein, said gene being fused to the pol-polyprotein gene; (ii) transcription and translation of the genes; and (iii) release of the integrase-fusion protein from the pol-polyprotein. | 09-02-2010 |
20110052540 | Non-Aggregating Virus Formulation - The present invention is a composition comprising a virus, a polyol and a zwitteronic compound. The present invention is also an assay for viral aggregation, which comprises analysing the size of the viral particles in a sample, wherein the particles are in admixture with a polyol, and determining from the size whether the sample contains substantially only acceptable, non-aggregated particles. | 03-03-2011 |
20110144013 | VEGF-D Mutants and Their Use - The present invention is a VEGF-D protein, containing one or more amino acid mutations at the dimer interface, and their use in therapy, particularly in the promotion of angiogenesis. | 06-16-2011 |
20120308522 | Therapeutic Use of Growth Factor, and Delivery Device, Especially for the Treatment of Intimal Hyperplasia - Vascular endothelial growth factor (VEGF) has utility in the treatment of intimal hyperplasia, hypertension and atherosclerosis, and of conditions susceptible to treatment with agents that produce nitric oxide or prostacyclin. Instead of VEGF, an equivalent agent such as an agonist of VEGF receptors may be given, as may nucleic acid encoding such an agonist. The agent may successfully be administered via the adventitial surface of a blood vessel, e.g. using a device which defines a reservoir between the body wall and the vessel's adventitial surface, the reservoir being at least part-filled by a pharmaceutical formulation containing the agent to be delivered. | 12-06-2012 |
20130296407 | Combination Therapy for Cancer - An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished. | 11-07-2013 |
20130310444 | Combination Therapy for Cancer - An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning the another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished. | 11-21-2013 |
20130331442 | Combination Therapy for Cancer - An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished. | 12-12-2013 |
20140017202 | Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity - Treating cancer of a organ located in a mesothelium-lined body cavity (i.e., lung, kidney, adrenal gland, ovary, prostate, pancreas or bladder cancer) by irrigating the mesothelium-lined body cavity with a solution containing a recombinant viral gene therapy vector bearing an interferon transgene, optionally administered shortly before administering chemotherapy and/or COX-2 inhibitor. | 01-16-2014 |
20140017204 | Transfection of Mesothelium Body Cavity Lining with Gene Agents Followed by Chemotharapy to Treat Cancer of Organs in the Body Cavity - Treating cancer of a organ located in a mesothelium-lined body cavity (i.e., lung, kidney, adrenal gland, ovary, prostate, pancreas or bladder cancer) by irrigating the mesothelium-lined body cavity with a solution containing a recombinant viral gene therapy vector bearing an interferon transgene, optionally administered shortly before administering chemotherapy and/or COX-2 inhibitor. | 01-16-2014 |
20140057851 | Anti-Angiogenic Gene Therapy With Soluble VEGF Receptors -1, -2 and -3 Together With Paclitaxel Prolongs Survival Of Mice With Human Ovarian Carcinoma - Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control, combination of AdsVEGFR-1, -2 and -3, combination of AdsVEGFR-1, -2, -3 and paclitaxel, bevacizumab monotherapy, paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival compared to the controls and all other treatment groups (p=0.001). Tumors of the mice treated by gene therapy were significantly smaller than in the control group (p=0.021). The mean vascular density and total vascular area were also significantly smaller in the tumors of the gene therapy group (p=0.01). | 02-27-2014 |